All In Biotech

Drug Trial Radar · NCT06484829

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

An Open-Label, Parallel-Controlled, Multi-Center Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of Purinostat Mesylate for Injection Combined With Pomalidomide Capsules and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Mar 25, 2024

Primary completion

Feb 1, 2026

Study completion Apr 1, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Purpose Phase Ib. To determine the Maximum Tolerated Dose (MTD) and establish the Recommended Phase IIa Dose (RP2D) of Purinostat Mesylate for Injection combined with fixed-dose Pomalidomide Capsules and Dexamethasone in patients with relapsed or refractory multiple myeloma. Phase IIa. To further evaluate the safety and tolerability of Purinostat Mesylate for Injection at the RP2D combined with fixed-dose Pomalidomide Capsules and Dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM). Secondary Objectives Phase Ib 1. To evaluate the safety and tolerability of Purinostat Mesylate for Injection combined with fixed-dose Pomalidomide Capsules and Dexamethasone in the treatment of relapsed or refractory multiple myeloma. 2. To assess the pharmacokinetic (PK) parameters of the combination therapy in patients with relapsed or refractory multiple myeloma. 3. To observe the preliminary efficacy of the combination therapy in patients with relapsed or refractory multiple myeloma. Phase IIa 1. To evaluate the preliminary efficacy of the combination therapy in patients with relapsed and refractory multiple myeloma (RRMM). 2. To characterize the population pharmacokinetic (PPK) profile of the combination therapy in patients with relapsed or refractory multiple myeloma (RRMM).

Conditions

  • Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions

  • Purinostat Mesylate 4 mg/m2Drug

    4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

  • Purinostat Mesylate 6 mg/m2Drug

    6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

  • Purinostat Mesylate 8.4 mg/m2Drug

    8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: Day 21/Day 28
  2. Maximum Tolerated Dose (MTD)Time frame: Day 21/Day 28
  3. Objective remission rate (ORR)Time frame: Day 21/Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.